Table 1:

Patient Characteristics

	All patients (n=23) N (%)
Median age at time of treatment start, years (range)	64 (44-92 years)
Gender
Male	18 (78%)
Female	5 (22%)
Primary tumor type
Melanoma	7 (30%)
Non-small cell lung cancer	4 (17%)
Renal cell cancer	4 (17%)
Bladder	3 (13%)
Prostate	2 (9%)
Colorectal	1 (4%)
Hepatocellular	1 (4%)
Merkel cell cancer	1 (4%)
Symptoms
Numbness	8 (35%)
Paresthesia	13 (57%)
Pain	14 (61%)
Weakness	12 (52%)
Neuropathy on exam	8 (35%)
Muscle cramps and pain	2 (9%)
Ptosis and diplopia	4 (17%)
Dysarthria	1 (4%)
Dyspnea	1 (4%)
Median time to onset of neurotoxicity, weeks (range)	5 (1-43 weeks)
Doses of ICI received prior to onset, median (range)	2 (1-20 doses)
Treatment
Neuropathic pain medications	12 (52%)
Corticosteroids	19 (83%)
IVIG or plasmapheresis	5 (22%)
Hospitalization	12 (52%)

ICI: immune checkpoint inhibitor; IVIG: intravenous immunoglobulin